Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Shionogi to Take Part in GSK-Pfizer JV, Realigns Strategy in HIV Field
October 30, 2012
-
BUSINESS Chugai to License SGLT-2 Inhibitor to Kowa, Sanofi
October 29, 2012
-
BUSINESS Janssen’s New MR Training System Aims to Produce “Consulting MRs”
October 29, 2012
-
REGULATORY MHLW to Initially Limit Number of Stores to Offer Epadel OTC
October 26, 2012
-
BUSINESS “Changing Way of Thinking Necessary among Industry, Government, Academia for Promotion of Drug Discovery”: AZ Chairman Kato
October 25, 2012
-
BUSINESS Santen Going on Offensive in Growth Fields in Ophthalmology
October 24, 2012
-
BUSINESS Astellas Poised for Domestic PIIb Trial of Novel IBS Treatment
October 23, 2012
-
BUSINESS MTPC to Dissolve Capital Alliance with Choseido
October 22, 2012
-
REGULATORY Sales Tax Hike Expected to Hasten Separation of Dispensing from Medical Practice by Sapping Yakka-Saeki
October 19, 2012
-
REGULATORY PAFSC Committee Recommends Approval for Switch OTC Version of Epadel 2 Years after Frist Review
October 18, 2012
-
BUSINESS Qol’s Mr Takada Hints at Continued Use of Long-Listed Drugs from Makers Hiring Apo Plus MRs
October 17, 2012
-
BUSINESS MTPC’s Oral MS Treatment Charging towards Blockbuster Territory
October 16, 2012
-
BUSINESS Towa Pharmaceutical Expanding Direct-Sales Network as Its Distributors Face Lack of Successors
October 15, 2012
-
ACADEMIA We Would Like to Provide iPS Cells with Medical History Identification: Prof. Yamanaka of Kyoto University
October 15, 2012
-
BUSINESS Radical AD Treatments Hit “PIII Wall” Again, but Amyloid β Hypothesis Remains Unshaken
October 15, 2012
-
REGULATORY MHLW to Begin Pilot Study on Drug Risk Management Plans for Generics
October 12, 2012
-
ORGANIZATION Price Gap between Long-Listed Products, Generics Necessary: FPMAJ Chairman Naito
October 11, 2012
-
BUSINESS Lack of Patient Satisfaction with BPH Treatments Offers Opportunity; Can Kissei Get Them to Switch to Urief?
October 11, 2012
-
BUSINESS Biz Entertainment Spending by MRs Falls at Most Companies, Down 80% at Foreign Firm: Jiho Poll
October 10, 2012
-
ORGANIZATION Life Science Budget in Japan Lacks Absolute Amount: JPMA President Teshirogi
October 10, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…